Modality
siRNA
MOA
MALT1i
Target
IL-17A
Pathway
PI3K/AKT
PBCHS
Development Pipeline
Preclinical
~Oct 2017
→ ~Jan 2019
Phase 1
~Apr 2019
→ ~Jul 2020
Phase 2
Oct 2020
→ Sep 2028
Phase 2Current
NCT08567557
2,817 pts·HS
2020-10→2028-09·Recruiting
2,817 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2028-09-102.4y awayPh3 Readout· HS
Trial Timeline
Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q4
P2/3
Recruit…
Catalysts
Ph3 Readout
2028-09-10 · 2.4y away
HS
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08567557 | Phase 2/3 | HS | Recruiting | 2817 | LiverFat |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-2735 | Johnson & Johnson | Phase 2/3 | Cl18.2 | |
| Riboinavolisib | Johnson & Johnson | Phase 2/3 | GLP-1R | |
| RHH-974 | Roche | Preclinical | JAK1 | |
| NVS-3297 | Novartis | Preclinical | CDK2 | |
| Geliderotide | Novartis | NDA/BLA | IL-17A | |
| ABB-8985 | AbbVie | Phase 2 | CD20 | |
| Tirasotorasib | Takeda | NDA/BLA | IL-17A | |
| GIL-9779 | Gilead Sciences | Phase 1 | IL-17A | |
| Sovarelsin | Alnylam | Phase 2/3 | LAG-3 | |
| ITC-6153 | Intra-Cellular | Phase 3 | KRASG12C |